Core Insights - Prime Medicine, Inc. (NASDAQ: PRME) has released positive data regarding its Prime Editing technology therapy PM359, which was used to treat a patient with Chronic Granulomatous Disease (CGD) [2] Company Overview - Prime Medicine specializes in innovative gene editing technologies, particularly focusing on Prime Editing, which has shown promise in treating genetic disorders [2] Treatment Details - The therapy PM359 was administered to a patient suffering from CGD, and the results indicate a successful application of the technology [2]